Inflammatory bowel disease: perceived impact on leisure-time activities

Figures & data

Table 1. Patient characteristics.

	total
Total sample	561
Age	53.2 years
cd	201 (35.8%)
UC	360 (64.2%)
Clinical data
biologics	67 (12.8%)
Corticosteroids	171 (32.9%)
antibiotics	31 (6.0%)
hospitalization	22 (4.2%)
ibdq score	172 (range 44–223, SD ± 34)
surgery due to ibd	117 (20.9%)
highest CRP	10 (range 1–276, SD ± 26)
Highest Calpro	652 (range 13–6000, SD ± 1119)

Table 2. Weekly hours spent in leisure-time activities, the percentage of patients that reported disadvantage in leisure-time activities due to IBD and the average level of limitations amongst the patients, who reported a limitation due to IBD.

	Weekly hours spent in leisure-time activities	Perceived limitation in any leisure-time activity	Level of limitation (VAS scale 0–100)
All	11.5	52.8%	36
Men	12.5	53.3%	30***
Women	10.5	52.3%	42***
Crohn	11.6	54.6%	39
Colitis	11.5	51.8%	35
Biologics	11.3	64.6%*	37
No-biologics	11.7	51.6%*	36
Operated	14.7**	52.9%	46**
Not operated	10.6**	53.1%	34**

*p < .05, **p < .01, ***p < .001.

Otherwise statistically not significant.

Table 3. The proportion of patients that reported being forced to reduce and abandon leisure-time activities due to IBD.

	Reduced leisure-time activities	Reduced physicial activities	Reduced activities with difficulties getting to toilet	Reduced other leisure-time activities	Abandoned leisure-time activities	Abandoned physical activities	Abandoned activities with difficulties getting to toilet	Abandoned other leisure-time activities
All	33.3%	24.0%	11.8%	5.0%	17.6%	11.2%	5.5%	2.7%
Men	31.1%	22.5%	9.2%	2.8%*	15.1%	9.9%	6.1%	2.5%
Women	35.5%	25.3%	14.4%	7.2%*	20.0%	12.3%	4.9%	2.9%
Crohn	33.5%	21.4%	11.9%	7.5%*	22.3%*	15.4%*	7.5%	3.5%
Colitis	33.1%	25.2%	11.7%	3.6%*	14.9%*	8.6%*	4.4%	2.2%
Biologics	44.8%*	32.8%	11.9%	6.0%	26.2%	22.4%**	4.5%	6.0%
No-biologics	32.4%*	23.5%	11.7%	4.6%	16.7%	9.7% **	5.8%	2.2%
Operated	36.2%	26.5%	12.8%	4.4%	25.0%*	19.7%**	6.8%	4.3%
Not operated	32.9%	23.6%	11.3%	7.7%	16.0%*	9.0%**	5.3%	2.3%

*p < .05, **p < .01, ***p < .001.

Otherwise statistically not significant.

Data availability statement

The data underlying this article will be shared on reasonable request to the corresponding author.